Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Allarity Therapeutics, Inc.

PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Reports Third Quarter 2022 Financial Results
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.